$11.73−0.77 (−6.16%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
MoonLake Immunotherapeutics (MLTX) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld. Worth your attention in FY25: Share count (+335.4%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▼90.0%
−230.3
FY21→FY25CAGR —
Free cash flow ($M)▼67.4%
−196.0
no value for 1 of 5 yearsCAGR —
Diluted EPS▼86.8%
−3.53
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+335.4%
14.8mn → 64.5mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$35.0K
−93.3% YoY in FY25.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
Margin trend · direction beats level
This filer reports no gross profit or operating income line, so those margins are not drawn.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.755, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Research & development | 229,613.0 | 202,862.0 | 112,771.0 | 31,802.0 | 42,049.0 | — | ▲79.9% | +69.0% |
Selling, general & admin | 47,140.0 | 41,972.0 | 30,320.0 | 22,321.0 | 23,012.5 | 4,570.3 | ▲38.4% | +74.1% |
Total operating expenses | 276,753.0 | 244,834.0 | 143,091.0 | 54,123.0 | 65,061.4 | 4,570.3 | ▲71.1% | +170.5% |
Operating incomefeeds ROC rank | −276,753.0 | −244,834.0 | −143,091.0 | −54,123.0 | −65,061.4 | −4,570.3 | ▼71.1% | — |
Other income, net | 4,270.0 | 15,124.0 | 22,129.0 | 10,138.0 | 591.7 | 27.7 | — | — |
Pretax income | −272,483.0 | −229,710.0 | −120,962.0 | −43,985.0 | −64,469.7 | −4,542.7 | ▼89.9% | — |
Income tax | 1,591.0 | 611.0 | 282.0 | 94.0 | 36.4 | — | ▲116.7% | +156.1% |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −274,074.0 | −230,321.0 | −121,244.0 | −44,079.0 | −64,506.1 | −4,542.7 | ▼90.0% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −3.65 | −3.53 | −1.89 | −0.73 | −1.70 | −0.31 | ▼86.8% | — |
Diluted shares (mn) | 85.38 | 64.46 | 62.87 | 49.12 | 29.36 | 14.80 | ▲2.5% | +44.5% |
| Margins | ||||||||
† TTM = trailing four quarters through 2026-09-30.
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-25 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

